vTv Therapeutics Inc.
No SEC Form 4 filings for $VTVT in the last 30 days.
See all $VTVT insider activity →RBC Capital's Brian Abrahams maintained a Hold rating on Kymera Therapeutics (KYMR) with a $112 price target, while LifeSci Capital's Patrick Dolezal initiated coverage on vTv Therapeutics (VTVT) with a Buy rating and $60 target. KYMR's consensus price target is $135.22, and VTVT's is $58.50.
vTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid
vTv Therapeutics (Nasdaq: VTVT) reported Q2 2026 results for the quarter ended June 30, 2026. The company said Phase 3 CATT1 cadisegliatin enrollment is expected to complete in Q3 2026 and it expects cash of $86.6M at June 30 to fund operations through the CATT1 topline readout. Q2 net loss was $13.1M, or $1.05/share.
Over the past 7 days, alphai's AI scored 1 news story mentioning VTVT (vTv Therapeutics Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VTVT coverage spans financial news, earnings and corporate actions.
New coverage and higher target could spark buying pressure.
The filing provides a concrete clinical timeline and cash runway, which can re-rate probability-weighted outcomes ahead of the CATT1 topline.
Near-term catalyst is the Phase 3 CATT1 enrollment completion timeline and the implied funding runway into topline data.
The filing is a routine equity-compensation inducement grant; it modestly increases share-based dilution risk but is not tied to new clinical/regulatory milestones.
The filing is a corporate-governance update (annual meeting results) with limited direct fundamental impact.
alphai scores every news story that mentions VTVT with an AI model for sentiment and relevance, and aggregates insider trades from vTv Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RBC Capital's Brian Abrahams maintained a Hold rating on Kymera Therapeutics (KYMR) with a $112 price target, while LifeSci Capital's Patrick Dolezal initiated coverage on vTv Therapeutics (VTVT) with a Buy rating and $60 target. KYMR's consensus price target is $135.22, and VTVT's is $58.50.
2 min readvTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid
5 min readvTv Therapeutics (Nasdaq: VTVT) reported Q2 2026 results for the quarter ended June 30, 2026. The company said Phase 3 CATT1 cadisegliatin enrollment is expected to complete in Q3 2026 and it expects cash of $86.6M at June 30 to fund operations through the CATT1 topline readout. Q2 net loss was $13.1M, or $1.05/share.
5 min readvTv Therapeutics (Nasdaq: VTVT) said it granted inducement stock options to two non-executive employees under Nasdaq Rule 5635(c)(4): 12,500 options with a weighted average exercise price of $34.15. Options vest over four years (25% at one year, then quarterly for 36 months) and expire after 10 years, subject to plan terms.
2 min readvTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. vtvt-20260626 FALSE 0001641489 Nasdaq 0001641489 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event rep
2 min readvTv Therapeutics Inc. announced the grant of 39,500 stock options to two new non-executive employees as an inducement to employment, in compliance with Nasdaq Listing Rule 5635(c)(4). These options have a weighted average exercise price of $32.00 per share and will vest over four years, subject to continued employment. The company is a late-stage biopharmaceutical firm focused on developing cadisegliatin for type 1 diabetes.
2 min readvTv Therapeutics is holding its 2026 annual virtual-only meeting on June 10, 2026, where stockholders will vote on electing seven directors and ratifying Ernst & Young LLP as the independent auditor. The proxy statement details the company's governance structure, board composition, director compensation, and executive compensation for 2025, including CEO Paul Sekhri's $6.64 million total compensation and CFO Michael Tung's $2.44 million. Key investors, including MacAndrews & Forbes and several institutional investors, hold significant stakes and have board nomination rights.
3 min readThis article details five new analyst initiations on various stocks, including Jabil, Rush Street Interactive, Enovix, Planet Fitness, and vTv Therapeutics. Baird initiated coverage on Jabil with an Outperform rating and a $275 price target, while other analysts issued ratings ranging from Buy to Neutral for the other companies. These initiations offer investors fresh perspectives and price targets for these companies.
3 min readThe average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2 min readvTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min read
